| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.10.1.87 |
| P698 | PubMed publication ID | 15757405 |
| P2093 | author name string | Paolo Prandoni | |
| P2860 | cites work | Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 |
| Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials | Q31039948 | ||
| Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study | Q33895888 | ||
| A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. | Q33967251 | ||
| Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran | Q33973559 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism | Q35859662 | ||
| Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q35895168 | ||
| Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. | Q43597590 | ||
| Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators | Q43681404 | ||
| Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study | Q44086372 | ||
| Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism | Q44175857 | ||
| Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction | Q44235192 | ||
| Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group | Q44421412 | ||
| Extended oral anticoagulant therapy after a first episode of pulmonary embolism. | Q44496670 | ||
| Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism | Q44636976 | ||
| A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation | Q44724811 | ||
| Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor | Q44852505 | ||
| Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial | Q44917839 | ||
| A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire | Q47302513 | ||
| A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis | Q47334930 | ||
| Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. | Q47409250 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. | Q53299395 | ||
| The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. | Q53361537 | ||
| A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. | Q53374794 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 87-94 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging strategies for treatment of venous thromboembolism | |
| P478 | volume | 10 |
| Q43042778 | Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism. | cites work | P2860 |
Search more.